London
· Delayed Price · Currency is GBP · Price in USD Inovio Pharmaceuticals Statistics
Total Valuation
LON:0A43 has a market cap or net worth of GBP 51.63 million. The enterprise value is -10.29 million.
| Market Cap | 51.63M |
| Enterprise Value | -10.29M |
Important Dates
The next estimated earnings date is Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +22.49% |
| Shares Change (QoQ) | +6.58% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 33.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 296.84 |
| PB Ratio | 0.94 |
| P/TBV Ratio | 0.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.12 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.12 |
Financial Position
The company has a current ratio of 2.77, with a Debt / Equity ratio of 0.17.
| Current Ratio | 2.77 |
| Quick Ratio | 2.70 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.11 |
| Interest Coverage | -632.05 |
Financial Efficiency
Return on equity (ROE) is -115.42% and return on invested capital (ROIC) is -61.64%.
| Return on Equity (ROE) | -115.42% |
| Return on Assets (ROA) | -49.45% |
| Return on Invested Capital (ROIC) | -61.64% |
| Return on Capital Employed (ROCE) | -144.34% |
| Revenue Per Employee | 1,298 |
| Profits Per Employee | -639,339 |
| Employee Count | 134 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.42% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -83.42% |
| 50-Day Moving Average | 1.88 |
| 200-Day Moving Average | 4.63 |
| Relative Strength Index (RSI) | 56.20 |
| Average Volume (20 Days) | 3,814 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.96 |
Income Statement
In the last 12 months, LON:0A43 had revenue of GBP 173,937 and -85.67 million in losses. Loss per share was -3.15.
| Revenue | 173,937 |
| Gross Profit | -60.23M |
| Operating Income | -89.78M |
| Pretax Income | -85.67M |
| Net Income | -85.67M |
| EBITDA | -88.38M |
| EBIT | -89.78M |
| Loss Per Share | -3.15 |
Balance Sheet
The company has 75.18 million in cash and 9.48 million in debt, giving a net cash position of 65.70 million.
| Cash & Cash Equivalents | 75.18M |
| Total Debt | 9.48M |
| Net Cash | 65.70M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 54.72M |
| Book Value Per Share | 1.52 |
| Working Capital | 49.93M |
Cash Flow
In the last 12 months, operating cash flow was -83.13 million and capital expenditures -389,666, giving a free cash flow of -83.52 million.
| Operating Cash Flow | -83.13M |
| Capital Expenditures | -389,666 |
| Free Cash Flow | -83.52M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -51,616.90% |
| Pretax Margin | -49,254.26% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LON:0A43 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.49% |
| Shareholder Yield | -22.49% |
| Earnings Yield | -165.93% |
| FCF Yield | -161.77% |
Stock Splits
The last stock split was on January 25, 2024. It was a reverse split with a ratio of 0.0833333333.
| Last Split Date | Jan 25, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0833333333 |
Scores
LON:0A43 has an Altman Z-Score of -21.34. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -21.34 |
| Piotroski F-Score | n/a |